Chest
-
OSA & COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Healthcare costs are a major concern for individuals especially in the United States. The healthcare delivery system in the US is challenged with pressures to reduce costs while not diminishing access to high quality care. therefore ,we evaluated the impact of delayed diagnosis of OSA, on different co- morbidities, patient outcome and healthcare costs ⋯ The following authors have nothing to disclose: Ahmed FadilNo Product/Research Disclosure Information.
-
ILD Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Isolated extra-pulmonary manifestations of sarcoidosis occur in only 10% of cases. Exclusive splenic involvement is extremely rare; a review revealed only 5 prior cases reported in the literature. We report the case of a middle-aged female incidentally found to have splenomegaly on physical exam after presenting with non-specific constitutional symptoms. After extensive work-up, splenic resection confirmed sarcoidosis. One year follow-up revealed no development of pulmonary manifestations. ⋯ This case illustrates the importance of including sarcoidosis in the differential diagnosis of patients presenting with isolated splenomegaly and no pulmonary symptoms.Reference #1: Giovinale M, Fonnesu C, Soriano A, et al. European Review for Medical and Pharmacological Sciences 2009; 13(Suppl 1): 37-44.Reference #2: Zia H, Zemon H, Brody F. Journal of Laparoendoscopic & Advanced Surgical Techniques. April 2005, 15(2): 160-162.Reference #3: Warshauer DM, Lee JKT. AJR 2004; 182: 15-28DISCLOSURE: The following authors have nothing to disclose: Abhay Vakil, Hineshkumar Upadhyay, Khalid Sherani, Kelly Cervellione, Alan FeinNo Product/Research Disclosure Information.
-
DVT/PE/Pulmonary HypertensionSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 12:15 PM - 01:15 PMPURPOSE: The long-term effect of riociguat was compared in patients with CTEPH in FC I/II versus FC III/IV at CHEST-1 baseline. ⋯ Andrea M D'Armini: Other Andrea D'Armini received fees for participation in review activities from Bayer: Hossein-Ardeschir Ghofrani: Grant monies (from industry related sources) Hossein-Ardeschir Ghofrani has received grant money paid to his institution by Bayer HealthCare: Friedrich Grimminger: Grant monies (from industry related sources) Friedrich Grimminger has received grant money paid to his institution by Bayer HealthCare: Marius M Hoeper: Consultant fee, speaker bureau, advisory committee, etc. Marius M. Hoeper has received consulting fees, honorarium and/or support for travel from Bayer: Pavel Jansa: Consultant fee, speaker bureau, advisory committee, etc. Pavel Jansa has received consulting fees, honorarium and/or support for travel to meetings from Bayer: Nick H Kim: Consultant fee, speaker bureau, advisory committee, etc. Nick H. Kim has received consulting fees, honorarium and/or support for travel to meetings from Bayer: Gerald Simonneau: Grant monies (from industry related sources) Gerald Simonneau has received grant money paid to his institution from Bayer: Adam Torbicki: University grant monies Adam Torbicki has received university grant monies for statute activities of the university: Martin Wilkins: Consultant fee, speaker bureau, advisory committee, etc. Martin Wilkins has received consulting fees, honorarium and/or support for travel to meetings from Bayer HealthCare: Arno Fritsch: Employee Arno Fritsch is a full-time employee of Bayer HealthCare: Neil Davie: Employee Neil Davie is a full-time employee of Bayer HealthCare: Eckhard Mayer: Consultant fee, speaker bureau, advisory committee, etc. Eckhard Mayer has received consulting fees, honorarium and/or support for travel to meetings from Bayer The following authors have nothing to disclose: Chen WangNo Product/Research Disclosure Information.
-
Surgery Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Congenital anomalies of the lower respiratory tract are rare. Bronchopulmonary sequestration (BPS) is estimated to comprise 0.15 to 6.4% of all congenital pulmonary malformations, making it an extremely rare disorder. In several reports, even tertiary care referral centers diagnose less than one case per year. We report a rare congenital malformation known as BPS in an uncommon age range, middle aged adult. ⋯ Due to the relatively small prevalence and often asymptomatic presentation of this disease entity, one must have a heightened awareness of this process even in older adults. While it was not the case in our patient, this entity may be the unrecognized cause of recurrent pneumonias, abscesses, hemoptysis, and heart failure from persistent left-to-right shunting.Reference #1: Pryce DM. Lower accessory pulmonary artery with intralobar sequestration of lung: a report of seven cases. J Pathol Bacteriol.1946;58:457-467Reference #2: Gustafson, et al. Intralobar sequestration: a missed diagnosis. Ann Thorac Surg. 1989;47:841-84DISCLOSURE: The following authors have nothing to disclose: Anita Rajagopal, Edward Mintz, Anthony AsciotiNo Product/Research Disclosure Information.
-
Randomized Controlled Trial Multicenter Study
A validated risk model to predict 90-day VTE events in post-surgical patients.
VTE is the proximate cause of 100,000 deaths in the United States each year. Perioperative VTE risk among surgical patients varies by 20-fold, which highlights the importance of risk stratification to identify high-risk patients, in whom chemoprophylaxis can decrease VTE risk, and low-risk patients, for whom the risk-benefit relationship of prophylaxis may be unfavorable. ⋯ A weighted risk index quantifies 90-day VTE risk among surgical patients and identifies an 18-fold variation in VTE risk among the overall surgical population.